TaiLai Biosciences

Cutting-edge multi-omics platform developing liquid biopsy assays

Shanghai, China

About the company

Tailai Biosciences is an incubation project sponsored by Ruifu partners. By leveraging its proprietary cutting-edge multi-omics platform, TaiLai has independently developed a series of liquid biopsy assays that are marketed today and designed to detect cancer earlier to prevent disease or to diagnosis and treat in the early stages of disease. It has screened hundreds of thousands of patients and is able to double its revenue every year. The company is partnering with Guizhou government for early cancer screening.